This measure assesses the proportion of adult patients who are prescribed short-term dual antiplatelet therapy upon discharge following a diagnosis of high-risk transient ischemic attack (TIA), minor non-embolic ischemic stroke, or intracranial large artery atherosclerosis. It encourages the use of evidence-based protocols to reduce the risk of recurrent stroke.